REMD-456A
/ REMD Bio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
Targeted optimized interferon alpha demonstrates improved safety and efficacy in tumors with low PD-L1 expression
(AACR 2025)
- "REMD-456 was selected for its efficacy and safety profile in vitro and in vivo and manufacturability. It showed enhanced IFN activity only on PD-L1+ cells, resulting in an improved therapeutic window. In vivo, REMD-456 demonstrated superior anti-tumor efficacy in human tumor xenografts."
Clinical • IO biomarker • Oncology • IFNA1 • IFNAR1 • PD-L1
1 to 1
Of
1
Go to page
1